Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17256314 | 0.96 | TSHR (0.58) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL10867521 | 0.96 | TSHR (0.58) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL20958118 | 0.96 | TSHR (0.58) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL20958160 | 0.96 | TSHR (0.58) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL6720040 | 0.86 | TSHR (0.58) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL1991359 | 0.85 | TSHR (0.78) | TSHRNAAAIDO1TACR1AGXT | |
| SCHEMBL1319297 | 0.85 | TSHR (0.56) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL8609519 | 0.83 | L3MBTL1 (0.54) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL10011934 | 0.83 | L3MBTL1 (0.54) | TSHRNAAAALDH1A1HPGDALOX15 | |
| SCHEMBL11070232 | 0.83 | L3MBTL1 (0.54) | TSHRNAAAALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744424-B | A kind of preparation method of ticagrelor midbody | 博瑞生物医药（苏州）股份有限公司 | 2018-12-25 | — | — | CN | claimed |
| CN-104744424-A | Preparation method of ticagrelor intermediate | BRIGHTGENE BIO MEDICAL TECHNOOGY CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-102863373-B | Method for synthesizing 5-benzylazaspiro[2,4]heptane | SUZHOU KANGRUN PHARMACEUTICAL CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-102863373-A | Method for synthesizing 5-benzylazaspiro[2,4]heptane | SUZHOU KANGRUN PHARMACEUTICAL CO LTD | 2013-01-09 | — | — | CN | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4727914-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| EP-0664289-A2 | Isoquinolines | SANDOZ LTD. (CH) | 1995-07-26 | — | — | EP | disclosed |
| CN-1105799-A | Carbostyril derivatives as matrix metalloproteinases inhibitors | OTSUKA PHARMA CO LTD (JP) | 1995-07-26 | — | — | CN | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
| US-4766213-A | 1,4-dihydropyridines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4049811-A | MICROBIOCIDES | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-09-20 | — | — | US | disclosed |
| US-4012429-A | OXYTOCICS, ANTISECRETORY AGENTS | SANKYO COMPANY LIMITED (JA) | 1977-03-15 | — | — | US | disclosed |
| US-3966743-A | ANTIMICROBIAL | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | TSHR 4311/4885NAAA 2858/4885ALDH1A1 3638/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | TSHR 1916/4885NAAA 3089/4885ALDH1A1 3667/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | TSHR 4557/4885NAAA 2523/4885ALDH1A1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.